Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2022-08-15 | Forward | 7:6 |
Nutriband Inc., founded in 2016 in Orlando, Florida, develops transdermal pharmaceutical products, including an abuse-deterrent fentanyl system for chronic pain and RAMBAM transfer devices through licensing agreements.

Nutriband's lead product is an abuse-deterrent fentanyl transdermal patch using AVERSA technology with aversive agents to prevent misuse, diversion, and accidental exposure.
| Icon | PRODUCT | Q1-2022 |
|---|---|---|
![]() | TransdermalPatchesMember | $401.99K |
![]() | ContractServicesMember | $75.93K |
| Map | REGION | Q1-2025 | Q2-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $667.43K | $614.92K ▼ | $746.67K ▲ | $433.4K ▼ |
![]() | Foreign Member | — | $7.63K | — | — |
Overall rating: C
| PEER | PRICE | |
|---|---|---|
RLYB | $16.94 | COMPARE |
BOLD | $2.85 | COMPARE |
IBIO | $1.31 | COMPARE |
NRSN | $0.48 | COMPARE |
PLUR | $1.44 | COMPARE |
INTS | $4.10 | COMPARE |
CVKD | $1.23 | COMPARE |